40
40
50
50
71
71
52
52
49
49
18
18
14
14
21
21
16
16
18
18
2019
2010
Foundation (697)University (246)Research Institution (184)Company (152)Hospital (139)Other (8)
1 - 10 of 697
Sort by
Publication
ID32371537Published Date2020-05-05JournalClinical cancer research : an official journal of the American Association for Cancer Research, 2020-05-05
In NSABP B-41, pathologic complete response (pCR) was associated with prolonged survival among women with HER2-positive operable breast cancer treated with neoadjuvant chemotherapy and lapatinib, trastuzumab, or the combination. We used a large human breast cancer gene expression panel to select candidate prognostic biomarkers for pCR among women treated with trastuzumab in NSABP B-41.Eligible patients had a baseline pre-adjuvant treatment core biopsy sample, known pCR status, and no withdraw…
Patent
Publication NumberUS 10619215Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-08-11Publication Date2020-04-14
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Publication
ID32085892Published Date2020-04-01JournalAnnals of oncology : official journal of the European Society for Medical Oncology, 2020-04-01, Volume 31
Since 2004, adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX or FLOX) have been the standard of care for patients with resected colon cancer. Herein we examine the change of outcomes over a 10-year period in patients with stage III colon cancer who received this regimen.Individual patient data from the ACCENT database was used to compare the outcomes in older (1998-2003) and newer (2004-2009) treatment eras for patients with stage III colon cancer who received adjuvant FOLFOX or F…
Patent
Publication NumberAU 2017228579 B2Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-09-13Publication Date2019-12-12
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer. 9394737_1 (GHMatters) P59406.AU.4
Patent
Publication NumberAU 2019261715 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-11-06Publication Date2019-11-28
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer. 9394737_1 (GHMatters) P59406.AU.4
Publication
ID31722153Published Date2019-11-14JournalThe New England journal of medicine, 2019-11-14, Volume 381
Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.We randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no…
Publication
ID31428908Published Date2019-11-01JournalBreast cancer research and treatment, 2019-11-01, Volume 178
NSABP B-41, a phase three randomized trial, evaluated neoadjuvant lapatinib, trastuzumab, or the combination with chemotherapy in patients with HER2-positive operable breast cancer. Though no significant difference in pathologic complete response (pCR) was found among the three arms, pCR was associated with prolonged survival. We analyzed tumor intrinsic subtypes with Prediction Analysis of Microarray 50 in a subset of B-41 patients to determine their value in predicting HER2-targeting benefi…
Publication
ID31627744Published Date2019-10-18JournalJournal for immunotherapy of cancer, 2019-10-18, Volume 7
The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To address this gap, we examined exome-capture RNA sequencing data from 50 primary breast tumors (PBTs) and their patient-matched metastatic tumors (METs) in brain, ovary, bone and gastrointestinal tract. We used gene expression signatures as su…
Publication
ID31987401Published Date2019-09-01JournalAnnals of oncology : official journal of the European Society for Medical Oncology, 2019-09-01, Volume 30
Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAF complicates the association.Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAF status were analyzed. The primary end point was survival after recurrence (SAR). Associations of markers with SAR were analyzed using Cox proportional…
We found 697 documents that match your Search
Research Grants: 76
Publications: 412
Patents: 121
Clinical Trials: 88

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in